Eisai Initiates Preparation for New Drug Application, Based on the Results of an Investigator-Initiated Clinical Trial of Ultrahigh-Dose Mecobalamin for Amyotrophic Lateral Sclerosis in Japan
TOKYO, May 10, 2022 – (JCN Newswire) – Eisai Co., Ltd. today announced that it…